icd 10 code for breo ellipta

Full Answer

What is the ICD-10 code for inhaled steroid?

ICD-10 code Z79. 51 for Long term (current) use of inhaled steroids is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .

What is the ICD-10 code for steroid injection?

Long term (current) use of systemic steroids The 2022 edition of ICD-10-CM Z79. 52 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.

What is R68 89 diagnosis code?

ICD-10 code R68. 89 for Other general symptoms and signs is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .

Is Z76 89 a billable code?

Z76. 89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

What is the ICD-10 code for use of prednisone?

Z79. 5 - Long term (current) use of steroids | ICD-10-CM.

What is the ICD-10 code for injection?

ICD-10 code T80 for Complications following infusion, transfusion and therapeutic injection is a medical classification as listed by WHO under the range - Injury, poisoning and certain other consequences of external causes .

What is the ICD-10 code for signs and symptoms?

The ICD-10 code range for General symptoms and signs R50-R69 is medical classification list by the World Health Organization (WHO).

What is Z00 01?

ICD-10 code Z00. 01 for Encounter for general adult medical examination with abnormal findings is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .

What is the ICD-10 code for annual physical exam?

Z00.00ICD-10 Code for Encounter for general adult medical examination without abnormal findings- Z00. 00- Codify by AAPC.

When do you use ICD-10 code Z76 89?

Persons encountering health services in other specified circumstancesZ76. 89 is a valid ICD-10-CM diagnosis code meaning 'Persons encountering health services in other specified circumstances'. It is also suitable for: Persons encountering health services NOS.

What is the ICD-10 code for medication management?

ICD-10-PCS GZ3ZZZZ is a specific/billable code that can be used to indicate a procedure.

What is the ICD-10 code for medication refill?

ICD-10 Code for Encounter for issue of repeat prescription- Z76. 0- Codify by AAPC.

What is Breo 100/25?

for COPD. Once-daily BREO 100/25 is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. BREO is not used to relieve sudden breathing problems and won't replace a rescue inhaler.

Can you substitute Breo?

No substitutions are permitted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the amount received by the patient through this offer. Offer must be presented along with a valid prescription for BREO at the time of purchase.

Can you use Breo in children?

BREO should not be used in children and adolescents. It is not known if BREO is safe and effective in children and adolescents younger than 18 years of age. Do not use BREO if you have a severe allergy to milk proteins or are allergic to any of the ingredients in BREO. Ask your healthcare provider if you are not sure.

Does Breo have vilanterol?

BREO contains vilanterol. LABA medicines such as vilanterol when used alone increase the risk of hospitalizations and death from asthma problems. BREO contains an ICS and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems.

Does Breo have ICS?

BREO contains an ICS and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems. BREO contains vilanterol. LABA medicines such as vilanterol when used alone increase the risk of hospitalizations and death from asthma problems. Collapse.

Is Breo a prescription?

Once-daily BREO is a prescription medicine for adults with asthma who need both an ICS (inhaled corticosteroid) and a LABA (long-acting beta 2 -adrenergic agonist) medicine. BREO is not for people whose asthma is well controlled on an asthma control medicine, like an ICS.

Is Breo Ellipta covered by insurance?

ELIGIBILITY: Patients may be eligible for this offer if they have commercial insurance and insurance does not cover the full cost of the prescription or if they are not insured and are responsible for the cost of their prescriptions.

How many blisters are in Breo ellipta?

BREO ELLIPTA is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips, each with 30 blisters (or 14 blisters for the institutional pack). One strip contains fluticasone furoate (100 or 200 mcg per blister), and the other strip contains vilanterol (25 mcg per blister). A blister from each strip is used to create 1 dose. The inhaler is packaged within a moisture-protective foil tray with a desiccant and a peelable lid in the following packs: NDC 0173-0859-10 BREO ELLIPTA 100/25 30 inhalations (60 blisters) NDC 0173-0859-14 BREO ELLIPTA 100/25 14 inhalations (28 blisters), institutional pack NDC 0173-0882-10 BREO ELLIPTA 200/25 30 inhalations (60 blisters) NDC 0173-0882-14 BREO ELLIPTA 200/25 14 inhalations (28 blisters), institutional packStore at room temperature between 68°F and 77°F (20°C and 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children.BREO ELLIPTA should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use. Discard BREO ELLIPTA 6 weeks after opening the foil tray or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.

Is breo elliptano carcinogenic?

BREO ELLIPTANo studies of carcinogenicity , mutagenicity, or impairment of fertility were conducted with BREO ELLIPTA; however, studies are available for the individual components, fluticasone furoate and vilanterol, as described below.Fluticasone FuroateFluticasone furoate produced no treatment-related increases in the incidence of tumors in 2-year inhalation studies in rats and mice at inhaled doses up to 9 and 19 mcg/kg/day, respectively (approximately 0.5 times the MRHDID in adults on a mcg/m2 basis). Fluticasone furoate did not induce gene mutation in bacteria or chromosomal damage in a mammalian cell mutation test in mouse lymphoma L5178Y cells in vitro. There was also no evidence of genotoxicity in the in vivo micronucleus test in rats.No evidence of impairment of fertility was observed in male and female rats at inhaled fluticasone furoate doses up to 29 and 91 mcg/kg/day, respectively (approximately 3 and 8 times, respectively, the MRHDID based on AUC) [see Use in Specific Populations (8.1)].VilanterolIn a 2-year carcinogenicity study in mice, vilanterol caused a statistically significant increase in ovarian tubulostromal adenomas in females at an inhalation dose of 29,500 mcg/kg/day (approximately 8,750 times the MRHDID in adults on an AUC basis). No increase in tumors was seen at an inhalation dose of 615 mcg/kg/day (approximately 530 times the MRHDID in adults on an AUC basis).In a 2-year carcinogenicity study in rats, vilanterol caused statistically significant increases in mesovarian leiomyomas in females and shortening of the latency of pituitary tumors at inhalation doses greater than or equal to 84.4 mcg/kg/day (greater than or equal to approximately 45 times the MRHDID in adults on an AUC basis). No tumors were seen at an inhalation dose of 10.5 mcg/kg/day (approximately 2 times the MRHDID in adults on an AUC basis). These tumor findings in rodents are similar to those reported previously for other beta-adrenergic agonist drugs. The relevance of these findings to human use is unknown.Vilanterol tested negative in the following genotoxicity assays: the in vitro Ames assay, in vivo rat bone marrow micronucleus assay, in vivo rat unscheduled DNA synthesis (UDS) assay, and in vitro Syrian hamster embryo (SHE) cell assay. Vilanterol tested equivocal in the in vitro mouse lymphoma assay. No evidence of impairment of fertility was observed in male and female rats at inhaled vilanterol doses up to 31,500 and 37,100 mcg/kg/day, respectively (approximately 5,490 times the MRHDID based on AUC).

Can Breo ELLIPTA cause rash?

Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA. Discontinue BREO ELLIPTA if such reactions occur. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder medications containing lactose; therefore, patients with severe milk protein allergy should not use BREO ELLIPTA [see Contraindications (4)].

Is Breo ELLIPTA safe for asthma?

BREO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma. BREO ELLIPTA has not been studied in subjects with acutely deteriorating COPD or asthma. The initiation of BREO ELLIPTA in this setting is not appropriate.COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If BREO ELLIPTA 100/25 no longer controls symptoms of bronchoconstriction; the patient’s inhaled, short-acting, beta2-agonist becomes less effective; or the patient needs more short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting a reevaluation of the patient and the COPD treatment regimen should be undertaken at once. For COPD, increasing the daily dose of BREO ELLIPTA 100/25 is not appropriate in this situation.Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of BREO ELLIPTA with a higher strength, adding additional ICS, or initiating systemic corticosteroids. Patients should not use more than 1 inhalation once daily of BREO ELLIPTA.BREO ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. BREO ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.When beginning treatment with BREO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and to use them only for symptomatic relief of acute respiratory symptoms. When prescribing BREO ELLIPTA, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient on how it should be used.

Is Breo Ellipta a long term asthma medication?

BREO ELLIPTA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA).Important Limitation of UseBREO ELLIPTA is NOT indicated for the relief of acute bronchospasm.

Is Breo Ellipta safe for thyrotoxicosis?

BREO ELLIPTA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

NDC Package Code 0173-0859-10

The NDC Code 0173-0859-10 is assigned to a package of 1 tray in 1 carton > 1 inhaler in 1 tray > 30 powder in 1 inhaler of Breo Ellipta, a human prescription drug labeled by Glaxosmithkline Llc. The product's dosage form is powder and is administered via respiratory (inhalation) form.

National Average Drug Acquisition Cost (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average drug invoice price paid by retail community pharmacies to wholesalers. The Centers for Medicare and Medicaid Services (CMS) compile the NADAC data based on random monthly surveys on more than 60,000 pharmacies from all 50 states and the District of Columbia.

Other Product Packages

The following packages are also available for Breo Ellipta with product NDC 0173-0859.